New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
07:04 EDTTRVNTrevena initiates TRV734 clinical development
Trevena announced the initiation of its first Phase 1 trial for TRV734. TRV734 is being developed to optimize analgesia while minimizing on-target gastrointestinal and respiratory effects through its novel biased ligand mechanism at the mu-opioid receptor. TRV734 takes advantage of the same receptor specificity mechanism as does Trevena’s Phase 2 clinical candidate, TRV130. The main objective of this first-in-human trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of TRV734 in healthy subjects. The potentially efficacious dose range of TRV734 will also be evaluated using pupilometry, a validated biomarker for mu-opioid receptor engagement.
News For TRVN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2015
16:26 EDTTRVNOn The Fly: Top stock stories for Tuesday
Stocks began the session deep in negative territory and remained there throughout the session. The weakness was attributed to the release of poor economic data out of China that confirms the world's second largest economy is slowing. There was little help from the day's domestic economic reports, as the construction spending and ISM manufacturing data came out roughly in-line with expectations. The market pared its losses slightly just before the lunch hour, but then the sellers regained control and pushed the averages down further with no sign of a rally prior to the close. ECONOMIC EVENTS: In China, the government's official manufacturing purchasing manager's index fell to 49.7 in August, indicating contraction and marking its worst PMI reading in three years. In the U.S., the Institute for Supply Management's manufacturing index for August came in at 51.1, below the consensus forecast for a reading of 52.5. Markit's manufacturing PMI for last month came in at 53.0 in its final reading, slightly beating expectations for a 52.9 reading. Construction spending rose 0.7% in July, beating/missing expectations for spending to have grown 0.6% in the month. In Europe, the final Eurozone manufacturing PMI for August came in at 52.3, which was a tick down from the flash reading of 52.4 and from July's final 52.4 reading. The EU's statistics agency said the eurozone's unemployment rate fell to 10.9% during July, marking the area's lowest unemployment figure since February 2012. COMPANY NEWS: Ford (F) reported August U.S. sales that it said were its best in nine years, growing its sales by 5% to 234,237 vehicles last month, but its shares slipped 1.08% to $13.72 amid the broader market weakness. General Motors (GM) fell 2.75% to $28.63 after the company reported its U.S. sales slipped 0.7% to 270,480 vehicles in August, while Fiat Chrysler (FCAU) shares slid 3.4% to $13.65 after the company reported its U.S. sales increased 1.7% last month to 201,672 units... Shares of streaming video giant Netflix (NFLX) fell $9.39, or 8.16%, to $105.64 after Variety reported that Apple (AAPL) is exploring an entry into the original programming business and Amazon (AMZN) announced it expanded Prime Video downloads to the iOS and Android platforms. MAJOR MOVERS: Among the notable gainers was drugmaker Trevena (TRVN), which surged 51% to $9.06 after reporting that its study of post-surgery painkiller TRV130 met its primary endpoint. Also higher was Internap (INAP), which gained 12% to $8.93 after disclosing that it is exploring strategic alternatives. Among the noteworthy losers was Penn West (PWE), which declined about 16.5% to 64c after suspending its dividend and announcing plans to cut its global workforce by 35% amid the weak commodity price environment. Also lower were both Westport (WPRT) and Fuel Systems (FSYS), which lost a respective 5.93% and 4.23%, after agreeing to merge and reiterating current revenue outlooks for both companies. Additionally, Dollar Tree (DLTR) fell 9.2% to $69.22 after its pre-market earnings report. Note that in a regulatory filing last night, the company disclosed that it does not plan to pay a dividend following its combination with Family Dollar. INDEXES: The Dow dropped 469.68, or 2.84%, to 16,058.35, the Nasdaq lost 140.40, or 2.94%, to 4,636.10, and the S&P 500 fell 58.33, or 2.96%, to 1,913.85.
12:21 EDTTRVNOn The Fly: Top stock stories at midday
Subscribe for More Information
12:07 EDTTRVNAnalysts bullish on Trevena after TRV130 Phase 2b trial meets primary endpoint
Subscribe for More Information
10:33 EDTTRVNTrevena upgraded to Overweight from Equal Weight at Barclays
Subscribe for More Information
09:25 EDTTRVNOn The Fly: Pre-market Movers
Subscribe for More Information
08:50 EDTTRVNTrevena data positive, says JMP Securities
Subscribe for More Information
August 31, 2015
18:32 EDTTRVNOn The Fly: After Hours Movers
UP AFTER EARNINGS: Matrix Service (MTRX), up 6%... Bazaarvoice (BV), up 4.1%. ALSO HIGHER: Trevena (TRVN), up 32.2% after the Phase 2b study of TRV130 achieved its primary endpoint... Sunedison (SUNE), up 3.6% after Point72 reports a 5.1% passive stake in the company. LOWER: Adept Technology (ADEP), down 3.5% after reporting quarterly results and saying that the company's U.S. turnaround is taking longer than expected.
16:14 EDTTRVNTrevena up 32.5% after Phase 2b study of TRV130 achieved primary endpoint
Subscribe for More Information
16:05 EDTTRVNTrevena CEO sees starting Phase 3 development of TRV130 in early 2016
Subscribe for More Information
16:04 EDTTRVNTrevena reports Phase 2b study of TRV130 achieved primary endpoint
Trevena announced data from its randomized, double-blind, placebo- and active-controlled Phase 2b trial of TRV130 in moderate to severe acute postoperative pain after abdominoplasty surgery. The study achieved its primary endpoint of statistically greater pain reduction than placebo over 24 hours. In addition, TRV130 was superior to morphine in pre-specified secondary measures, exhibiting significantly reduced nausea, vomiting, and hypoventilation events. TRV130 demonstrated statistically significant pain reduction compared to placebo and comparable efficacy to morphine. The TRV130 0.1 mg regimen reduced average pain scores by 2.3 points. The TRV130 0.35 mg regimen reduced average pain scores by 2.1 points, similar to morphine, which reduced average pain scores by 2.1 points. TRV130 provided rapid reduction in average pain scores, consistent with the previous Phase 2 trial where TRV130 showed more rapid onset of meaningful pain relief than morphine. Rescue analgesic use was similar for both TRV130 and morphine, and less than half the rate of rescue analgesic use for placebo.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use